Provided by Tiger Fintech (Singapore) Pte. Ltd.

Shuttle Pharmaceuticals Inc

0.3700
-0.0580-13.55%
Post-market: 0.37000.00000.00%19:17 EDT
Volume:1.65M
Turnover:722.62K
Market Cap:1.82M
PE:-0.09
High:0.3987
Open:0.3568
Low:0.3402
Close:0.4280
Loading ...

Company Profile

Company Name:
Shuttle Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
9
Office Location:
401 Professional Drive,Suite 260,Gaithersburg,Maryland,United States
Zip Code:
20879
Fax:
- -
Introduction:
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Directors

Name
Position
Anatoly Dritschilo
Chairman of the board and Chief Executive Officer
Bette Jacobs
Independent Director
Chris Senanayake
Independent Director
Joshua Schafer
Independent Director
Steven Richards
Independent Director
Milton Brown
Director

Shareholders

Name
Position
Anatoly Dritschilo
Chairman of the board and Chief Executive Officer
Peter Dritschilo
President and Chief Operating Officer
Timothy J. Lorber
Chief Financial Officer
Michael Vander Hoek
VP for Operations and Regulatory
Mira Jung
Chief Scientific Officer
Tyvin Rich
Chief Clinical Officer